TheraRadar
← Back
Data updated: Jun 28, 2026

HOFFMAN-LA ROCHE

Biotech
Pharmaceuticals

HOFFMAN-LA ROCHE is a biotechnology company with 1 FDA-approved products.

2007
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

HOFFMAN-LA ROCHE's Key Drugs

HOFFMAN-LA ROCHE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

HOFFMAN-LA ROCHE's Recent FDA Approvals

New NDA/BLA approvals for HOFFMAN-LA ROCHE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HOFFMAN-LA ROCHE's Therapeutic Areas

Disease areas where HOFFMAN-LA ROCHE has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

HOFFMAN-LA ROCHE Pipeline Snapshot

Active clinical trials for HOFFMAN-LA ROCHE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling